FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:922-923 September 24, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Belshe, R. B.

To the Editor: The encouraging results of the study conducted by Belshe et al. (May 14 issue)¹ of a live attenuated influenzavirus vaccine that can be administered intranasally to young children should be placed in context. In an earlier study, we randomly assigned 5210 normal, healthy subjects to receive either attenuated or inactivated influenzavirus vaccine or placebo.² The study subjects, who were 1 to 65 years of age, received a total of 12,500 doses of vaccine over a five-year period. In contrast to the observation by Belshe et al. that the serologic response was poorer to the A/Texas/36/91-like (H1N1) component . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.